Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HRS-2129 tablets in acute gouty arthritis
CTR20262652Phase 2Active
- Sponsor
- Shandong Sende
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-2129 in acute gout flare, sponsored by Shandong Sende. Started Aug 2026; status: active.
02
Drugs
HRS-2129
03
Conditions
acute gout flare
Beyond the preview
Go deeper on CTR20262652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262652.